MSKCC Foundations in Immunotherapy in the Oncology Population 2026

Comprehensive Immuno-Oncology Course

📌 Overview

The Memorial Sloan Kettering Cancer Center Foundations in Immunotherapy in the Oncology Population 2026 is a high-impact, evidence-based course focused on modern cancer immunotherapy and its clinical applications.

Delivered by experts from Memorial Sloan Kettering Cancer Center, this program provides a deep dive into checkpoint inhibitors, CAR T-cell therapy, and emerging immunotherapy strategies, with a strong emphasis on real-world toxicity management and patient outcomes .

📦 Course Details

• 🎥 23 Video Lectures (.mp4)
• 📝 23 Subtitles (.vtt)
• 📄 20 PDF Slides
• 💾 Total Size: 4.97 GB
• 📅 Date: January 28, 2026 (Online CME Program)

🎯 Target Audience

• Oncologists (medical, hematologic, solid tumor)
• Immunotherapy specialists
• Nurse practitioners & physician assistants
• Hospitalists and oncology care teams

🧠 What You’ll Learn

🧬 Core Immunotherapy Principles

• Immune system fundamentals (innate vs adaptive)
• Mechanisms of action of checkpoint inhibitors
• Key targets: PD-1, PD-L1, CTLA-4

🎯 Advanced Immunotherapy Modalities

• CAR T-cell therapy
• Bispecific antibodies (BiTEs)
• Tumor-infiltrating lymphocytes (TILs)
• Novel immune agonists

🧪 Clinical Applications Across Cancers

• Solid tumors (lung, breast, bladder, melanoma)
• Hematologic malignancies (leukemia, lymphoma, myeloma)
• Personalized treatment strategies

⚠️ Toxicity & Adverse Event Management

• Immune-related adverse events (irAEs)
• Cytokine release syndrome (CRS)
• Neurotoxicity (ICANS)
• Dermatologic and pulmonary toxicities

🧠 Precision Oncology & Biomarkers

• cfDNA and predictive biomarkers
• Patient selection and risk stratification
• Treatment response monitoring

🔬 Emerging Innovations

• Combination immunotherapy strategies
• Next-generation checkpoint inhibitors
• Expanding indications across tumor types

🎓 Learning Objectives

By completing this course, participants will be able to:

• Understand core mechanisms of cancer immunotherapy
• Apply immunotherapy strategies in clinical oncology
• Differentiate between various immunotherapeutic agents
• Manage toxicities and complications effectively
• Integrate CAR T-cell therapy into clinical practice

📚 Key Topics Included

• Mechanism of checkpoint blockade (PD-1 / PD-L1 / CTLA-4)
• CAR T-cell therapy and toxicity management
• Immunotherapy in leukemia, lymphoma, and solid tumors
• Pneumonitis and dermatologic toxicity management
• Small cell lung cancer innovations
• Bladder, breast, and GI cancer immunotherapy
• Bispecific antibodies in multiple myeloma
• Synovial sarcoma and T-cell therapies
• CRS, ICANS, and cytopenias
• Case-based Q&A discussions

⭐ Why This Course Stands Out

• ✔️ From world-leading cancer center (MSKCC)
• ✔️ Covers both fundamentals + cutting-edge therapies
• ✔️ Strong focus on real clinical toxicity management
• ✔️ Case-based learning with practical insights
• ✔️ Relevant for daily oncology practice

🚀 Clinical Value

This course is essential for clinicians who want to:

• Stay updated with rapidly evolving immunotherapy landscape
• Improve patient selection and treatment outcomes
• Reduce complications through early toxicity recognition
• Apply precision oncology approaches in practice

4. Topics

1. Advancing CAR T-Cell Strategies and Combination Therapies to Improve Outcomes in Gynecologic Malignancies

2. Advancing Leukemia Care Through Immuno-Oncology

3. Approaches to Immunotherapy-related Pneumonitis Management

4. Breast Oncology- Using cfDNA to Forecast Immunotherapy Treatment Outcomes

5. Checkpoint Inhibition as a Therapeutic Approach in Advanced Hodgkin Lymphoma

6. Clinical Approaches to Dermatologic Toxicity in Checkpoint Inhibitor Therapy

7. Discussion of Novel Checkpoint Inhibitors and Combination Therapy

8. Dostarlimab in MSI-High Gastrointestinal Cancers- Latest Data, Expansion Cohorts, and Basket Trial Insights

9. Evolving Treatment Paradigms- Immunotherapy in Advanced Bladder Cancer

10. IL-2-Stimulating Agents from Early Drug Development

11. Innovations in Small Cell Lung Cancer- DLL3 Agents and Adjuvant Durvalumab

12. Intrathecal Immunotherapy- A Novel Path in Treating Leptomeningeal Disease no video

13. Mechanism of Action of Checkpoint Blockade PD1, PDL1, CTLA-4

14. Melanoma Subtypes are a Microcosm for Immune Checkpoint Blockade Efficacy Across Oncology-

15. Neurotoxicity in CAR T-Cell Therapy- Recognition and Management

16. Overview of Adverse Events in the Cell Therapy Patient- A Discussion of CRS, ICANS, and Prolonged Cytopenias

17. Q&A and Discussion – 01

18. Q&A and Discussion – 02

19. Q&A and Discussion – 03

20. Q&A and Discussion – 04

21. Q&A and Discussion

22. Targeting Multiple Myeloma with Bispecific Immune-Modulating Agents

23. The Role of T-Cell Therapy in Standard Care for Synovial Sarcoma

24. Understanding Chimeric Antigen Receptor (CAR) T-Cell Therapy